Apogee Therapeutics (APGE) said Monday that interim phase 1 data for its APG333 antibody "exceeded trial objectives," demonstrating a half-life of about 55 days, supporting potential dosing every three and six months.

APG333, which is being developed for the treatment of inflammatory and immunology conditions, was also well tolerated across all cohorts, with doses of up to 1,000 mg, the company said.

Apogee shares were 2.7% higher in recent trading.

Price: 56.25, Change: +1.54, Percent Change: +2.81